2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Andrew J. Armstrong, MD, discusses the utility of pamiparib and other PARP inhibitors in prostate cancer.
Andrew J. Armstrong, MD, professor of medicine, associate professor in pharmacology and cancer biology, and professor in surgery at Duke University School of Medicine, and member of the Duke Cancer Institute, discusses the utility of pamiparib and other PARP inhibitors in prostate cancer.
Pamiparib is a PARP inhibitor that is in development for multiple cancers, including prostate cancer, says Armstrong. The agent has a unique development plan; it’s an active PARP inhibitor that is being developed by BeiGene. The agent has not yet received FDA approval but it has entered phase II testing in a multicenter fashion in the United States, adds Armstrong. The trial examining its use is now open at Duke.
This agent offers an opportunity where the phenotype may possibly capture more than just BRCA2 mutation testing, concludes Armstrong.